Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus

PLoS Neglected Tropical Diseases

Volumn 7, Issue 12, 2013, Pages

  Mire, Chad E ^a,b   Geisbert, Joan B ^a,b   Marzi, Andrea ^c   Agans, Krystle N ^a,b   Feldmann, Heinz ^c   Geisbert, Thomas W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT VESICULAR STOMATITIS VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; MACACA; MALE; MORTALITY; NONHUMAN; PRIMATE; UREA NITROGEN BLOOD LEVEL; VACCINATION; VESICULAR STOMATITIS VIRUS; VIREMIA;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MACACA; MALE; VACCINATION; VACCINES, SYNTHETIC; VESICULOVIRUS;

EID: 84892698411     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002600     Document Type: Article

References (44)

1. Feldmann H, Geisbert T.W., Jahrling P.B., et al., editor (2004) Filoviridae. London: Elsevier/Academic Press. 645-653 p.
2. Feldmann H, Sanchez A., Geisbert T.W., editor (2013) Filoviridae: Ebola and Marburg Viruses. 6th ed. Philadelphia: Lippincott Williams and Wilkins. 923-956 p.
3. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4: e1000212.
4. Hartman AL, Towner JS, Nichol ST, (2010) Ebola and marburg hemorrhagic fever. Clin Lab Med 30: 161-177.
5. Outbreak news. Ebola haemorrhagic fever, Uganda. Wkly Epidemiol Rec 87: 339.
6. Outbreak news. Ebola haemorrhagic fever, Democratic Republic of the Congo. Wkly Epidemiol Rec 87: 338-339.
7. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, et al. (1995) Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345: 1271-1274.
8. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, et al. (1990) Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335: 502-505.
9. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A, (1998) Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251: 28-37.
10. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ, (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
11. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
12. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
13. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, et al. (2006) Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80: 9659-9666.
14. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3: e177.
15. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26: 6894-6900.
16. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83: 7296-7304.
17. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, et al. (2010) Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 84: 10386-10394.
18. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, et al. (2007) Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81: 6379-6388.
19. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 15: 460-467.
20. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, et al. (2008) Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 7: 417-429.
21. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2: S430-437.
22. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, et al. (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4: e5547.
23. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 6: e1000904.
24. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, et al. (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17: 572-581.
25. Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, et al. (2011) Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 204 Suppl 3: S1082-1089.
26. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, et al. (2011) Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. J Virol 85: 4222-4233.
27. Richardson JS, Pillet S, Bello AJ, Kobinger GP, (2013) Airway delivery of an adenovirus-based ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 87: 3668-3677.
28. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 110: 1893-1898.
29. Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, et al. (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87: 4952-4964.
30. Lawson ND, Stillman EA, Whitt MA, Rose JK, (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92: 4477-4481.
31. Mire CE, Dube D, Delos SE, White JM, Whitt MA, (2009) Glycoprotein-dependent acidification of vesicular stomatitis virus enhances release of matrix protein. J Virol 83: 12139-12150.
32. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, et al. (2002) Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 195: 593-602.
33. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82: 5664-5668.
34. Geisbert TW, Bausch DG, Feldmann H, (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20: 344-357.
35. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17: 1128-1131.
36. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, et al. (2012) A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 4: 146ra107.
37. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, et al. (2011) Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 7: e1002304.
38. Miranda ME, Miranda NL, (2011) Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204 Suppl 3: S757-760.
39. Taniguchi S, Watanabe S, Masangkay JS, Omatsu T, Ikegami T, et al. (2011) Reston Ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis 17: 1559-1560.
40. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325: 204-206.
41. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, et al. (2012) Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2: 811.
42. Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, et al. (2011) Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 204: 200-208.
43. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367: 1399-1404.
44. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, et al. (2011) Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204 Suppl 3: S1066-1074.